PD-1-Targeted IL-2v Expands a Novel Stem-like T Cell Subset Distinct from Anti-PD-1 Therapy to Enhance Effector Differentiation
Tumor-draining lymph nodes serve as critical sites for the generation, maintenance and differentiation of stem-like CD8 T cells during antitumor immune responses. Recent evidence has shown that delivering interleukin-2 to PD1 stem-like CD8 T cells using PD1-IL2v, an immunocytokine combining PD-1 blockade and IL-2R agonism, promotes their differentiation into potent effector cells with enhanced…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
